Evaluating the Cost-Effectiveness of Once-Weekly Semaglutide 1  mg Versus Empagliflozin 25 mg for Treatment of Patients with Type 2 Diabetes in the UK Setting

ConclusionOnce-weekly semaglutide 1  mg was projected to be a cost-effective treatment option from a healthcare payer perspective compared with empagliflozin 25 mg for the treatment of patients with type 2 diabetes in the UK setting.

Source: Diabetes Therapy - January 9, 2021 Category: Endocrinology Source Type: research